StemCell Therapy

FDA Asks Companies to Recall Diabetes Drug Metformin

The Food and Drug Administration (FDA) is asking companies to recall the popular diabetes drug metformin due to an apparent cancer risk.

The FDA announced that a high level of a contaminant calledN-Nitrosodimethylamine (NDMA), which is linked to cancer, was found in some versions of the drug. NDMA was found in several batches of the extended-release form of the drug, which is often prescribed to control high blood sugar in patients with type 2 diabetes. However, Dr. Marilyn Tan, chief of the Stanford Endocrine Clinic, tells SurvivorNet that most people with diabetes who take metformin take the immediate release form of the drug, and that version is still considered safe.

RELATED: Heartburn Drug Zantac Must Be Fully Removed From Shelves

Metformin is the most commonly used drug for type 2 diabetes and its one of the most cost-effective, Dr. Tan says. for the vast majority of patients, this recall doesnt apply to the type that they are on.

In its announcement, the FDA recommends people who currently take the drug in the extended-release form continue to do so until they can be prescribed an alternative.

Patients should continue taking metformin tablets even after recalls occur, until they consult with their health care professional who can prescribe a replacement. Patients with type 2 diabetes could face dangerous health risks if they stop taking their prescribed metformin, the agency said in a press release.

Dr. Tan says patients who are currently on the extended-release form of metformin may be able to switch to the immediate release form of the drug with few issues.

In terms of medication efficacy, theyre both equally effective, Dr. Tan tells SurvivorNet. She also reiterated that until people on extended-release metformin can consult their physicians about changing their prescription, they should continue taking the drug.

RELATED: Why are There So Many Carcinogen Warning Labels on Products in California?

So, just how risky is extended-release metformin? Its important to understand what NDMA is first before addressing that concern.

NDMA is a chemical that can be unintentionally formed during various manufacturing processes, according to the Centers for Disease Control and Prevention (CDC). People can be exposed to low levels of NDMA in a variety of ways it can be found in foods like cured meats and fish, beer, tobacco smoke and even in some toiletry and cosmetic products. NDMA is labeled as a probable carcinogen, meaning it may cause cancer in humans.

Essentially, NDMA is all around us at low levels. When it comes to cancer risk, its difficult for medical professionals to say exactly how dangerous the substance is.

We dont really know long term exactly what the risk is we do know that there is some potential for cancer and liver issues, Dr. Tan says.

The FDA considers the chemical generally safe as long as exposure does not exceed a certain limit and people are not exposed for a long period of time.

To avoid potential dangers, the FDA regularly tests and monitors products like medications to ensure that they only contain what the agency considers to be safe levels of contaminants like NDMA. Earlier this year, the agency recalled popular heartburn drug Zantac over high NDMA levels. This new metformin recall comes after the agency determined that the extended-release form of the drug had NDMA levels that were above the FDAs acceptable intake limit.

The acceptable intake limit for NDMA is 96 nanograms per day for medications, according to the FDA.

Learn more about SurvivorNet's rigorous medical review process.

The FDA announced that a high level of a contaminant calledN-Nitrosodimethylamine (NDMA), which is linked to cancer, was found in some versions of the drug. NDMA was found in several batches of the extended-release form of the drug, which is often prescribed to control high blood sugar in patients with type 2 diabetes. However, Dr. Marilyn Tan, chief of the Stanford Endocrine Clinic, tells SurvivorNet that most people with diabetes who take metformin take the immediate release form of the drug, and that version is still considered safe.

Metformin is the most commonly used drug for type 2 diabetes and its one of the most cost-effective, Dr. Tan says. for the vast majority of patients, this recall doesnt apply to the type that they are on.

In its announcement, the FDA recommends people who currently take the drug in the extended-release form continue to do so until they can be prescribed an alternative.

Patients should continue taking metformin tablets even after recalls occur, until they consult with their health care professional who can prescribe a replacement. Patients with type 2 diabetes could face dangerous health risks if they stop taking their prescribed metformin, the agency said in a press release.

Dr. Tan says patients who are currently on the extended-release form of metformin may be able to switch to the immediate release form of the drug with few issues.

In terms of medication efficacy, theyre both equally effective, Dr. Tan tells SurvivorNet. She also reiterated that until people on extended-release metformin can consult their physicians about changing their prescription, they should continue taking the drug.

RELATED: Why are There So Many Carcinogen Warning Labels on Products in California?

So, just how risky is extended-release metformin? Its important to understand what NDMA is first before addressing that concern.

NDMA is a chemical that can be unintentionally formed during various manufacturing processes, according to the Centers for Disease Control and Prevention (CDC). People can be exposed to low levels of NDMA in a variety of ways it can be found in foods like cured meats and fish, beer, tobacco smoke and even in some toiletry and cosmetic products. NDMA is labeled as a probable carcinogen, meaning it may cause cancer in humans.

Essentially, NDMA is all around us at low levels. When it comes to cancer risk, its difficult for medical professionals to say exactly how dangerous the substance is.

We dont really know long term exactly what the risk is we do know that there is some potential for cancer and liver issues, Dr. Tan says.

The FDA considers the chemical generally safe as long as exposure does not exceed a certain limit and people are not exposed for a long period of time.

To avoid potential dangers, the FDA regularly tests and monitors products like medications to ensure that they only contain what the agency considers to be safe levels of contaminants like NDMA. Earlier this year, the agency recalled popular heartburn drug Zantac over high NDMA levels. This new metformin recall comes after the agency determined that the extended-release form of the drug had NDMA levels that were above the FDAs acceptable intake limit.

The acceptable intake limit for NDMA is 96 nanograms per day for medications, according to the FDA.

Learn more about SurvivorNet's rigorous medical review process.

Read the original:
FDA Urges Recall of Diabetes Drug Metformin Due to Cancer Link -- How Dangerous is the Medication? - SurvivorNet

A new market report by Verified Market Research on the Type 2 Diabetes Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Type 2 Diabetes Treatment sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.verifiedmarketresearch.com/download-sample/?rid=31462&utm_source=COD&utm_medium=007

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Type 2 Diabetes Treatment manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Type 2 Diabetes Treatment Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=31462&utm_source=COD&utm_medium=007

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Type 2 Diabetes Treatment. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Verified Market Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/Type-2-Diabetes-Treatment-Market/?utm_source=COD&utm_medium=007

Customization of the Report:

Verified Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Type 2 Diabetes Treatment market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Read more:
Type 2 Diabetes Treatment Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Trends, Opportunities and Forecast 2026 - Cole...

by: News Release & Posted By Staff | newsweb@everythinglubbock.com

(Nexstar Media Group/EverythingLubbock.com Staff)

LUBBOCK, Texas (NEWS RELEASE) The following is a news release from Texas Tech University:

As the coronavirus began to spread around the globe early this year and its death toll mounted, it became apparent patients with obesity and diabetes faced a disproportionately higher mortality rate.

Now, with a$160,000 grantfrom the National Science Foundation (NSF), aninternationally renowned obesity researcheratTexas Tech Universityand two colleagues are rapidly exploring why these two groups are more likely to be affected and whether a simple change might improve their odds of survival.

Dr. Nikhil Dhurandhar, professor and chair of theDepartment of Nutritional Sciences;Rajesh Khare, professor ofchemical engineeringand assistant dean for strategic initiatives in theEdward E. Whitacre Jr. College of Engineering; andVijay Hegde, a molecular and cell biologist and assistant professor of nutritional sciences, are using an innovative, interdisciplinary approach.

To determine why the coronavirus affects people with obesity, they will examine whether fat cells act as a reservoir to facilitate COVID-19 infection. To determine why it affects people with diabetes, they will examine whether certain diabetes medications might actually encourage infection by increasing the number of receptors the virus, SARS-CoV-2, uses to enter cells.

We hope to determine whether having a greater number of fat cells, as in obesity, may contribute to a greater severity of COVID-19, Dhurandhar said. Also, we should be able to identify diabetes drugs that do not promote infection. Thus, our research is expected to provide information to clinicians to make decisions about the use of diabetes medications.

In cases of people with COVID-19, medical providers may be able to switch from a diabetes drug that may potentially harm individuals due to its ability to promote SARS-CoV-2 infection, to a drug that is innocuous. This simple change may be able to save a lot of lives.

Khare will use a chemical-engineering-based molecular-modeling technique to determine how SARS-CoV-2 binds to cell receptors in the presence of various diabetes medications. Dhurandhar and Hegde will conduct biological experiments involving fat cells and diabetes medications.

The research is funded through the NSFsEarly-Concept Grants for Exploratory Research(EAGER) mechanism, which supports exploratory work in its early stages on untested, but potentially transformative, research ideas or approaches. Such work could be considered especially high risk high payoff in the sense that it involves radically different approaches, applies new expertise or engages novel disciplinary or interdisciplinary perspectives.

While the results may have worldwide ramifications, theyre particularly critical in the U.S., where two-thirds of adults have a higher-than-healthy body weight and about 42% have obesity, Dhurandhar said. About 85% of people with Type 2 diabetes have obesity.

There is an urgent need to understand the biology and mode of transmission of SARS-CoV-2 in the context of the existing obesity and its comorbidities, Dhurandhar said. We feel extremely grateful to be able to participate in a small way in a solution to a disease that has affected the entire world, and we also are excited about the possibility that our timely research may save many lives.

The first results are expected as soon as September.

(News release from Texas Tech University)

View original post here:
TTU researchers examining roles of obesity, diabetes in COVID-19 infection - KLBK | KAMC | EverythingLubbock.com

More than half of people who manage to lose 10% of their body weight also reverse their type 2 diabetes, according to a survey.

A Slimming World study for Diabetes Week which starts today polled members with the condition who had achieved the weight-loss milestone.

And 54% said they had reversed their type 2 diabetes with 60% able to stop or reduce their medication.

Tracy McCormack, from Fife, lost 16 stone 2lb on the healthy eating plan. She was diagnosed with type 2 diabetes in July, 2016.

Her GP gave her some serious advice.

Tracy, 52, said: I was told I needed to change my lifestyle or they couldnt guarantee I would still be here in five years time.

"I was completely shocked and knew this was the wake-up call I needed.

Ive now lost 16st 2lb and my health has improved dramatically my diabetes is in remission and my blood pressure is now normal.

I no longer need to take medication and I dont fall asleep in work any more.

Dr Jacquie Lavin, of Slimming World, said: The findings are especially important this Diabetes Week as new NHS research is reporting that people with diabetes face significantly higher risks after contracting coronavirus.

Read the original:
Obese mum told she could die in five years loses 16st and reverses her diabetes - Mirror Online

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Kathleen McGroddy-Goetz, Ph.D., as an independent member of its Board of Directors effective June 8, 2020. Dr. McGroddy-Goetz has extensive experience commercializing pioneering technologies spanning from microelectronics through cloud, advanced data analytics, AI, hardware, software, and middleware with an emphasis on healthcare and life sciences applications.

We welcome Kathy to our Board of Directors at this important next stage in Tandems evolution, said John Sheridan, president and CEO, Tandem Diabetes Care. She is a leader in creating transformative healthcare and life sciences solutions, which brings tremendous value to our Company as we advance our mission to improve the lives of people with diabetes.

Dr. McGroddy-Goetz has more than 25 years of experience leading global teams across business development, strategy, research and development, and product management.

She is currently the Global Head of Strategic Partnerships at Medidata Solutions, a Dassault Systems Company, and VP of Strategy, Partnerships and Alliances at Medidatas Acorn AI subsidiary.

Prior to her current positions, Dr. McGroddy-Goetz was Vice President of Global Strategic Partnerships and Solutions at IBM, where she played a critical role in creating and launching Watson Health. Dr. McGroddy-Goetz received a B.S. in Physics from SUNY Binghamton and a Ph.D. in Molecular Biophysics from Cornell University.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandems flagship product, the t:slim X2 insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.Follow Tandem Diabetes Care on Facebook at http://www.facebook.com/TandemDiabetes.Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

Visit link:
Tandem Diabetes Care Appoints Dr. Kathleen McGroddy-Goetz to Board of Directors - Business Wire

Veteran actress Sophie Lichaba is grateful to be alive, this after a recent hospital visit due to high blood-sugar levels. The star has been open about her struggle with diabetes which led to her being viciously cyberbullied.

Sophie recently told DRUM shes in a better space after all the online bullying she endured following her drastic weight loss a result of living with diabetes.

Read more | Sophie Lichaba on how lockdown has affected her restaurant and shisanyama businesses

On Sunday, Sophie took to Instagram to thank God for the gift of life. Today I'm reminded that God is king of my life my heart. So grateful for the constant restoration.

Her diabetes diagnosis means shes at high risk during the Covid-19 pandemic, and shes not taking any chances. Some families have lost their loved ones. Im living with diabetes and most vulnerable to this pandemic. Im still here. So grateful. But from tomorrow and lockdown level 3, lets be responsible, she wrote.

Sophie applauded frontline workers and said she had seen their hard work firsthand due to a recent hospital visit.

I have seen an emergency room once in this delicate time, and it was just high sugar levels. The doctors, the nurses, the caregivers, the police, the army who daily sacrifice themselves. They all have families who need them too. We pray for you. Thank you.

She ended her post by reminding followers to remember the fight is not over and to wear your mask.

See her post here:

Read more: Sophie Ndaba on the reception of her role on Lockdown: My work speaks for itself

Reports that the actress is in debt have been dogging her for a while. In a recent interview with DRUM, Sophie didnt deny owing banks money but she said it was nowhere near the kind of financial trouble tabloid headlines suggested.

R150 000 is nothing. Not so long ago I owed the bank millions. Right now, my business probably owes R75 000 here and a couple of thousand there but thats old debt. Whoever dug up that information for the tabloids caught it too late because Im left with a few years of paying off what I owe, she added. By the grace of God, thats all in the past.

She told DRUM her financial troubles started when she first got diabetes, and even though she had fallen on hard times shes back on track. Through the grace of God, Im finding my feet again and nothing of mine will be repossessed, she said.

Continue reading here:
Sophie Lichaba on living with diabetes during the Covid-19 pandemic: Im still here, so grateful - News24

1. Obesity only preadmission factor to influence COVID-19 outcomes in diabetes  medwireNews
2. COVID-19 provides opportunity for digital innovation in diabetes care  Health Europa
3. One in 10 hospitalized COVID-19 patients with diabetes die by day seven, study finds  MinnPost
4. 10% With Diabetes Hospitalized for COVID-19 Die Within a Week  Medscape
5. COVID-19 Comorbidities: Diabetes is Among the Top Three  Diabetes In Control
6. View Full Coverage on Google News

See the rest here:
Obesity only preadmission factor to influence COVID-19 outcomes in diabetes - medwireNews

FOX 2 - A Taylor woman's life has been changed forever because of COVID-19 and now she is in dire need of help. She will need to be moved to an acute rehab facility but not many are willing to take here because she had the virus.

"It is a lot, it is really overwhelming," said Wanavia Wilson. "Some nights I just cried all night, I didn't know what to do."

A Taylor woman's life has been changed forever because of COVID-19 and now she is in dire need of help.

Wanavia Wilson has been by her daughter's side since mid-May. Shantel Wilson, a 25-year-old mother of two small children, suffers from Type 1 diabetes. On May 12th she went to sleep and her blood sugar dropped to dangerous levels.

"When she is awake she notices the symptoms, the shakiness, the dizziness and she'll go and tested herself and eat something if it is low, because she was sleeping when it happened. She just kept sleeping and never woke up. (She was in a coma) for four days."

Doctors told her mother that Shantel suffered severe brain damage. Although she didn't have any symptoms, a routine test also revealed Shantel had COVID-19, which may have caused her blood to drop. She is now at Beaumont Farmington.

"She needs neurological therapies, speech therapy, physical therapy and occupational therapy," Wanavia said. "Because her sugar was low for an undetermined amount of time, they said they said going that long caused significant damage to both sides of her brain and it affecting her speech and her behaviors. So right now, she is basically a child again."

Shantel will need to be moved to an acute rehab facility, but her mother says because she had coronavirus - no facility has been willing to take her.

"Things were starting to pick up for her," her mother said. "I was so happy and so proud of her when she bought her first house. I was so proud of her when she got her degree, and I was like things are going so well for you and then (this)."

Wanavia has been off work because of the pandemic and has been doing what she can to scrape enough money together to care for Shantel's young son and prepare her home to care for her daughter, who won't be able to do anything for herself.

She has started a GoFundMe page to help offset some of the costs. Wanavia knows so many people are struggling right now, but says anything would be appreciated.

"As a parent you want the best for your kids and it is just hard when you see your kid struggling," she said. "She is very stubborn, very smart, very hard working. I am hoping and praying that thing about her that makes her so stubborn and such a fighter., will help her get past this."

Shantel said her first words today. If you would like to contribute, GO HERE.

View original post here:
Mother of 2 with diabetes gets coronavirus and is left with brain damage - FOX 2 Detroit

People with diabetic retinopathy experience depression at higher rates than the general population, but the rate decreases at the most severe stage of the disease, an analysis of a large database shows.

Although the study did not establish cause and effect, it alerts clinicians to explore the ways that the emotional wellness of a patient might be intertwined with eye disease, said Daniel Olson, MD, from the University of North Carolina in Chapel Hill.

"I believe in treating the whole patient, not just the eyeball," he told Medscape Medical News.

Olson became interested in the mental health of patients with diabetic retinopathy when he noticed their reactions during conversations about the course of the disease. "You see the anxiety and sadness building up in these patients," he said.

Previous studies have established an association between the eye disease and depression and anxiety. But the number of patients in these studies was not large enough to look at the association between mental health and some key subgroups.

To fill this gap, Olson and his colleagues analyzed a database of 95,575 people 18 years and older with eye exams on record at the Carolina Data Warehouse, a repository of all patients seen in the University of North Carolina system.

The team identified all patients with diagnoses of diabetic retinopathy, anxiety, depression, or some combination of these diseases, between July 2008 and July 2018 using International Classification of Diseases (ICD) codes. In the study cohort, 57.1% of the patients were women, 23.5% had diabetes mellitus, and 4.5% had diabetic retinopathy.

Of those without diabetic retinopathy, 18.7% had anxiety and 20.4% had depression, which is consistent with rates in the general population, Olson reported during his virtual presentation at the Association for Research in Vision and Ophthalmology 2020 Annual Meeting.

Among those who had a diagnosis of diabetic retinopathy, 21.5% had anxiety and 33.0% had depression. The rate of depression was significantly higher in those with diabetic retinopathy than in the general population, but the difference in the rate of anxiety was not significant.

This study is retrospective and does not provide a causal link between diabetic retinopathy and depression or anxiety, Olson acknowledged. It's possible that people become depressed when they are diagnosed with an eye disease, or conversely that depressed people don't take good care of their health, so their diabetes worsens, which leads to diabetic retinopathy.

To see if disease severity is associated with these mood disorders, the researchers looked at disease subsets: mild, moderate, and severe nonproliferative diabetic retinopathy, and proliferative diabetic retinopathy.

The risk for depression was 98% higher in patients with severe nonproliferative disease than in those without diabetic retinopathy. However, risk for depression was just 41% higher in patients who had progressed to proliferative disease.

A similar trend emerged for anxiety; the risk was significantly elevated only in patients with mild diabetic retinopathy.

Olson offered two possible explanations for the decline in depression and anxiety seen in patients in the most advanced stage of their disease.

First, patients might struggle to improve their exercise and diet without seeing results in the early stages of the disease. Then, once they advance to the proliferative stage and begin receiving treatment, they might realize that the treatments are not as bad as they feared. "They can calm down and not be as anxious or depressed," he said.

Second, patients with poor access to healthcare might not get treatment for diabetic retinopathy until it becomes proliferative and starts to affect their vision. Even if they are depressed, they might not see a primary care doctor, so their depression would not be documented in the database.

But such possibilities are speculative because the study does not show causation, cautioned Rahul Khurana, MD, assistant clinical professor of ophthalmology at the University of California, San Francisco.

"It's an interesting question to explore, but I'm not sure how we put it in the clinic," Khurana told Medscape Medical News.

For now, the work has already influenced Olson's interactions with his patients. He works closely with his patients' primary care physicians, and he listens more carefully.

"Rather than rattling off a list of things to do, which can be overwhelming to patients, I talk to patients about real ways they control the disease, and listen to their concerns so I can put them at ease about the course of the illness," he explained.

The study also showed that younger patients are more likely to experience anxiety than older patients, and men are more likely to experience depression than women.

"One reason for this may be that men are more visual creatures and the prospect of losing vision weighs more heavily on them," Olson said.

He said he would like to take the research further, following patients treated for both diabetic retinopathy and depression to see if depression treatment affects their retinopathy.

He has also found a similar association between mental health and age-related macular degeneration, and is exploring whether the number of injections a patient receives has any effect on mental health.

Association for Research in Vision and Ophthalmology (ARVO) 2020 Annual Meeting.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See the article here:
Diabetic Retinopathy Appears Linked to Depression - Medscape

LAS VEGAS, June 2, 2020 /PRNewswire/ -- Diabetic Peripheral Neuropathy Market will increase because of the rising global burden of diabetes that is driving prevalence of diabetic neuropathy, advancement in early diagnosis as well as launch of the promising therapies which will positively impact DPN market.

DelveInsight added a new report titled "Diabetic Peripheral Neuropathy MarketInsights, Epidemiology, and Market Forecast-2030" to its portfolio.

Key Highlights from Diabetic Peripheral Neuropathy Market report are:

Request for sample pages to know more onDiabetic Peripheral Neuropathy Epidemiology and Market Forecast

Diabetic Peripheral Neuropathy is a painful condition that is caused by nerve damage from diabetes. It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes.

There is a huge patient population pool affected by the disease; the Diabetic Peripheral Neuropathy market report covers the disease epidemiology that is segmented into Total Diagnosed Prevalent Cases of DPN, Total Prevalent Cases of Painful DPN and Gender-specific Prevalent cases of DPN in the 7MM from 2017 to 2030.

The total Painful Diabetic Peripheral Neuropathy Prevalent Cases were 3,857,945 in the United States in 2020. Also, females are more affected by the disease as compared to males for Diabetic Peripheral NeuropathyPrevalent in the US in 2020.

Click here to know more onDiabetic Peripheral Neuropathypipeline

Among the 7MM, the US accounts for 58% of the overall market size of DPN. Among the EU-5 countries, Germany accounts for the highest market size for DPN. Diabetic Peripheral Neuropathy market has a diverse pipeline with several promising therapies. Also, Gene therapy has been developed for DPN pain management. Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies. The potential launch of these emerging drugs will aid in overall market growth. There are a couple of market drivers which will be driving the market. One such factor will be an early diagnosis of the DPN because of the advancements happening in the DPN diagnostic approaches. As the patient pool for diabetic peripheral neuropathy is quite large, and there is no treatment for reversal of disease, this indication withholds a plethora of opportunities for drug development companies. No doubt that the clinical pipeline contains a large number of drugs; however, previously multiple clinical trial failures gave a setback and limited the research and development in the DPN domain. So far it has been clear that path traversed is not easy in DPN research as the long-term clinical trials and low success rate in meeting the clinical endpoints may become threats for the investors to fund further.

There aremany key players robustly involved in developing potential drugs and they are a ray of hopefor DPN patients such as:1. VM2022. NYX-29253. WST-0574. Ricolinostat5. ISC 175366. NRD135S.E17. Cebranopadol8. GRC 173569. MEDI735210. Trazodone/GabapentinAnd many others

The key players involved in Diabetic Peripheral Neuropathy market are:1. Helixmith2. Aptinyx3. WinSanTor, Inc4. Regenacy Pharmacuticals5. Ichnos Science6. Novaremed7. Grnenthal GmbH8. Glenmark Pharmaceuticals9. AstraZeneca10. AngeliniAnd many others

The reasons for buying Diabetic Peripheral Neuropathy market report:

Table of contents

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy Market Overview at a Glance

4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology

5. Diabetic Peripheral Neuropathy Disease Background and Overview

6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy in 7MM

6.3. United States

6.4. EU5

6.5. Germany

6.6. France

6.7. Italy

6.8. Spain

6.9. United Kingdom

6.10. Japan

7. Diabetic Peripheral Neuropathy Treatment and Management

8. Diabetic Peripheral Neuropathy Unmet need

9. Diabetic Peripheral Neuropathy Marketed Drugs

9.1. Key cross competition

9.2. Qutenza: Grnenthal

9.3. Tarlige: Daiichi Sankyo

10. Diabetic Peripheral Neuropathy Emerging drugs

10.1. Key cross competition

10.2. VM202: Helixmith

10.3. NYX-2925: Aptinyx

10.4. WST-057: WinSanTor

10.5. Ricolinostat: Regenacy Pharmaceuticals

10.6. Cebranopadol: Grnenthal

10.7. ISC 17536: Ichnos Science

10.8. NRD135S.E1: Novaremed

10.9. MEDI7352: AstraZeneca

10.10. Trazodone/Gabapentin: Angelini

11. Diabetic Peripheral Neuropathy Market Size

11.1. Key Findings

11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM

11.3. Diabetic Peripheral Neuropathy Market Outlook: 7 MM

11.4. United States

11.5. EU5

11.6. Germany

11.7. France

11.8. Italy

11.9. Spain

11.10. United Kingdom

11.11. Japan

12. Diabetic Peripheral Neuropathy Reimbursement policies

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. KOL Views

17. Diabetic Peripheral Neuropathy Case Report

18. A Case Report of Diabetic Peripheral Neuropathy

19. Bibliography

20. Appendix

21. Diabetic Peripheral Neuropathy Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Request a WebEx Demo to get a walk-through of the Diabetic Peripheral Neuropathy Market Report:https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market

Related Reports:

Diabetic Peripheral Neuropathy Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in the 7 MM.

Diabetic Peripheral Neuropathy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market.

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Contact us:

Shruti Thakurinfo@delveinsight.com+91-9650213330DelveInsight

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Read the original here:
Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight - P&T Community

Two thirds (67 per cent) of people with diabetes attending work do not feel safe, according to a new survey carried out among those with the condition.

More than half of respondents (54 per cent) to the Diabetes UK poll also say their employer is not enabling them to socially distance at work.

Since the lockdown started, the charity has seen unprecedented demand from people with diabetes seeking support on issues relating to employment and coronavirus through its helpline and support services.

The survey of almost 3,000 people with diabetes, revealed that almost half (45 per cent) of the people who are either currently at work, or are soon due to be returning to work outside of the home, reported not feeling confident in raising concerns about social distancing or safety at work with their employer.

The 3.9 million people diagnosed with diabetes in the UK are identified in the Governments list of clinically vulnerable groups, and the current advice is that people with diabetes should follow social distancing measures stringently, stay at home as much as possible, and minimise contact with those they do not live with.

A return to business as usual is not possible for people with diabetes, because of the lack of adequate safeguards from Government to ensure their safety Chris Askew

The new research also revealed that more than half of those working outside of home (57 per cent) do not know where they can get support from to resolve workplace safety issues.

A key element of the Governments recent employment guidance to protect workers, was the need for employers to carry out risk assessments for their employees, and make provisions to mitigate risk where it existed.

However Diabetes UKs survey found that this does not seem to be working in practice, as of those due to return to work, 60 per cent have not been consulted about a risk assessment that had been, or was in the process of being carried out, despite being in a clinically vulnerable group.

Diabetes UK does not believe the Governments employment guidance goes far enough to ensure safety at work for people with diabetes and those in other clinically vulnerable groups who are at increased risk of serious illness or death if they catch Coronavirus.

The charity is urgently calling for additional measures to ensure the safety of clinically vulnerable people at work.

Diabetes UKs Chief Executive Chris Askew said: A return to business as usual is not possible for people with diabetes, because of the lack of adequate safeguards from Government to ensure their safety.

With the new evidence on the increased risk for people with diabetes regarding COVID-19 Government must act now and review all the current guidelines and measures to keep people with diabetes and other clinically vulnerable groups safe. If lockdown continues to ease without specific and enforceable safeguards for people in clinically vulnerable groups in place, this pressure will only intensify further.

People with diabetes deserve to have their individual needs fully considered, with action taken to reduce any risk of coming into contact with the virus. A generic and catch-all assessment of workplace risks by employers does not go far enough and this evidence shows is not working in practice for people with diabetes.

The Government must ensure that employers take all the necessary measures to keep all employees safe, now and going forward if they are expected to attend work outside the home this includes clinically vulnerable people having a right to stay working from home if they do not feel safe.

Diabetes UK has written an open letter to the Secretary of State for Business, Energy and Industrial Strategy, urgently calling for more robust protections for clinically vulnerable workers and greater clarity for both employees and employers. The organisation is specifically calling for:

Photo by Ketut SubiyantofromPexels

Continued here:
Two thirds of those with diabetes do not feel safe at work - The Diabetes Times

More than 10% of people with diabetes and COVID-19 receive ventilator intubation and die within a week of hospitalization, say investigators. Higher body weight is independently linked to these outcomes, while glucose control is not, they report.

Diabetes is a known contributor to COVID-19 severity, but the characteristics that predict adverse outcomes in diabetes patients have been unclear, wrote Bertrand Cariou, M.D., Ph.D., from the University of Nantes, France. In a new study, Cariou and colleagues found that 10.6% of 1,317 participants died within seven days of hospital admission. And the higher a patients body mass index, the greater their risk.

A number of other factors also predicted seven-day mortality at admission. These included labored breathing, lymphocyte (white blood cell) count levels, and the presence of inflammation and liver damage markers.

In contrast, factors that had no significant bearing on seven-day intubation and mortality included age, sex, long-term glucose control, chronic complications, and hypertension or usual medications.

Only BMI turned out to be independently associated with the primary outcome, Cariou wrote. Each increase in BMI is associated with an increase in the risk of intubation and/or death in the seven days following admission for COVID-19. So lets target this population as a really important population to keep social distancing and stay alert on avoiding the virus.

The study was published Friday in the journal Diabetologia.

Go here to read the rest:
One in ten with diabetes die within week of COVID-19 hospitalization: Weight a key factor - Clinical Daily News - McKnight's Long Term Care News

In early 2020, it seemed like people with diabetes were disproportionately dying with COVID-19, but the data provided more questions than answers. What type of diabetes did people have? Were people dying because the condition itself put them at greater risk, or because those with it tend to be older and have other illnesses? And what should people with diabetes do to protect themselves?

Now, researchers are harnessing data from NHS England to address these questions and some of their findings are unexpected.

It is still unclear whether people with diabetes are more likely to catch the virus. We wont know if this is true until sustained, widespread testing is rolled out. But we do know that a disproportionate number of people with the condition have been hospitalised with COVID-19. In the UK, data spanning February to April shows people with diabetes made up approximately 25% of hospitalised cases; thats almost four times higher than the estimated rate of diabetes in the general population.

Once in hospital with COVID-19, data also shows that people with diabetes have worse outcomes than people without. The increase in risk is striking but isnt necessarily surprising people with diabetes are prone to worse outcomes from infections generally, as data from flu shows.

When it comes to COVID-19, early studies suggest people with diabetes are approximately twice as likely to be categorised as having severe disease and are more likely to be admitted to intensive care units. In England, one in four people who die in hospital with COVID-19 have diabetes.

Previous studies, however, didnt shed light on the details behind these headline statistics, and didnt break down data by diabetes type. We now have this information, and it shows a significant and surprising difference.

Compared to people without diabetes, people with type 1 diabetes are approximately 3.5 times as likely to die in hospital with COVID-19, while people with type 2 are approximately twice as likely. This came as a surprise to some, because, unlike type 1, type 2 diabetes is often accompanied by other diseases, typically comes on in older age, and can be associated with raised body weight. All of these factors are linked to worse outcomes from COVID-19.

There are a number of possible explanations as to why outcomes are worse in type 1 compared to type 2.

First, the length of time someone has had diabetes might impact their vulnerability to COVID-19. Unlike type 2, people are most often diagnosed with type 1 at a young age (I was diagnosed at ten). In people hospitalised with COVID-19, someone with type 1 has likely had diabetes for much longer than someone with type 2. The longer someone has diabetes, the more likely they are to have complications, which include damage to the heart and kidneys.

Second, in type 1, your immune system attacks the cells that make insulin and you eventually stop making insulin altogether. Insulin is the hormone that helps the body process sugar in the blood. Type 2 isnt a disease of the immune system. In type 2, your body makes insulin but is resistant to it. The immune systems of people with type 1 may be different from people with type 2, which could impact how people respond to infection.

Finally, data shows that higher blood sugar levels increase the risk of COVID-19. We know that on average blood sugar levels are higher in people with type 1 than with type 2 diabetes, because of the different nature of the diseases. Blood sugar levels can be even harder to manage when fighting infections.

But these are all just theories. We need more research before we know for sure how the type of diabetes impacts COVID-19 outcomes.

To illustrate this, Im going to use myself as an example and do some crude calculations. Im 36 and have type 1 diabetes. Most people with COVID-19 arent hospitalised. However, if hospitalised with COVID-19, the average 36-year-old has a 0.3% chance of dying. Because I have type 1 diabetes, my chances of dying are 3.5 times higher. That means my current chances of dying with COVID-19 once hospitalised are around 1%.

However, if the average 80-year-old is hospitalised with COVID-19, they have a 15% chance of dying. So, though diabetes does increase my risk, my age still remains the most important factor, by far, in determining my chances of dying with COVID-19. My risk at 80 would still be higher than someone of that age without diabetes, so both would need to be taken into account.

It is really important to note that these figures are not someones overall risk of dying from COVID-19, they are the risk of dying if they contract COVID-19 and if the infection is then severe enough to warrant hospitalisation.

The advice to people with diabetes is to practice social distancing and handwashing like the rest of the population, to maintain a healthy lifestyle, and to try to keep blood sugars in an ideal range where possible.

But aiming for tighter blood sugar control can feel daunting. Now might be a particularly difficult time for people to manage diabetes, with disruptions in care, routines, activity, mental wellbeing and diet known to create challenges. Certain groups will face more challenges than others; both COVID-19 and diabetes disproportionately affect people from non-white ethnic groups and people from less advantaged backgrounds.

Support is available from healthcare providers and from organisations like Diabetes UK. Now more than ever, governments and healthcare systems need to ensure all people with diabetes get the support they need.

View original post here:
Coronavirus and diabetes: the different risks for people with type 1 and type 2 - The Conversation UK

Loss of a pregnancy may increase a womans risk of developing Type 2 diabetes, Danish researchers report.

Their study, in Diabetologia, included 24,774 women who developed diabetes after pregnancy and 247,740 controls who did not.

Compared with women who had been pregnant without losing a baby, those who lost one were at an 18 percent increased risk for diabetes, those who lost two were at a 38 percent higher risk and those who lost three or more had a 71 percent higher risk. The study adjusted for obesity and gestational diabetes, which are known to be associated with the development of Type 2 diabetes.

The reason for the association remains unknown. It may be that the same genetic background increases the risk for both pregnancy loss and diabetes, or that pre-diabetes present before the diagnosis of diabetes could lead to both. In any case, the authors stress that the observational finding does not prove cause and effect.

The lead author, Dr. Pia Egerup, a researcher at the Recurrent Pregnancy Loss Unit of the Rigshospitalet and Hvidovre Hospital in Copenhagen, said that the most important clinical implication is that pregnancy loss is a risk factor for diabetes.

Pregnancy loss is not only due to fetal disease, she said. A large proportion are healthy fetuses lost because of maternal conditions. As clinicians, we want to optimize pregnancy success and minimize the risk for future diabetes.

See the original post here:
Pregnancy Loss Tied to Increased Risk of Type 2 Diabetes - The New York Times

By

MATTHEW PERRONE AP Health Writer

May 29, 2020, 7:30 PM

2 min read

2 min read

WASHINGTON -- U.S. health regulators are telling five drugmakers to recall their versions of a widely used diabetes medication after laboratory tests found elevated levels of a contaminant linked to cancer.

The Food and Drug Administration said late Thursday that several batches of the drug metformin tested positive for unsafe levels of a chemical called N-Nitrosodimethylamine. The agency has stepped up testing after the chemical was found in dozens of shipments of heartburn drugs last year, triggering recalls of Zantac and other popular over-the-counter and prescription medications.

Metformin tablets are a staple of diabetes care, reducing excess sugar in the blood. People with Type 2 diabetes use metformin alone or with other drugs to help control their blood sugar levels. More than 34 million people in the U.S. have this disease.

Patients should continue taking metformin drugs until their doctor can prescribe a replacement, the FDA said in a statement, noting the risks of discontinuing. Regulators are still assessing whether the recalls will lead to shortages of metformin, but noted that a number of other companies make generic versions of the drugs that don't appear to be affected by the issue.

Drugmaker Apotex Corp. recalled its extended-release metformin distributed in the U.S. earlier this week after the FDA found contamination in one lot. Apotex said in a statement it recalled all supplies of the drug out of an abundance of caution. The company said it stopped selling the drug in the U.S. in February 2019 and that little remains on the market.

The FDA announcement did not name the four other drugmakers who have been requested to recall their products.

The agency noted that no contamination problems have been found in immediate-release metformin.

The FDA is responsible for ensuring that medicines for the U.S. market are made in safe, sanitary conditions that meet federal quality standards. But government inspectors have repeatedly criticized the agency for falling short in reviewing overseas manufacturing plants as the pharmaceutical supply chain has increasingly spread to Asia.

In March, the FDA suspended nearly all U.S. and foreign inspections due to safety concerns and travel restrictions caused by the coronavirus outbreak.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Department of Science Education. The AP is solely responsible for all content.

Go here to read the rest:
FDA finds contamination in several brands of diabetes drug - ABC News

The time of puberty onset may help predict the risk of diabetes in men. The earlier boys experienced the onset of puberty, the higher their risk of developing type 2 diabetes as adults, reveals a new study, published in the journal Diabetologia in March 2020. Also Read - 40% of diabetic patients initially decline insulin therapy: All you need to know about this disease

The findings may help establish guidelines for prevention and testing for diabetes in men. It may also lead to new interventions against the chronic condition that affects the way your body metabolizes sugar (glucose). Also Read - Trigger finger and other surprising signs of type 2 diabetes you might be ignoring so far

For the study, the researchers the University of Gothenburg in Sweden assessed more than 30,600 Swedish men born between 1945 and 1961. They found that those who had their pubertal growth spurt at age 9.3 to 13.4 years had a twofold risk of developing early type 2 diabetes than those who had the growth spurt at the age of 14.8 to 17.9 years. Also Read - Suffering from type 2 diabetes? Watch what youre eating for your breakfast

For each year earlier that the pubertal growth spurt occurred, the risk of developing early diabetes went up by 28 per cent, while the risk of late diabetes increased by 13 per cent. Men who had early pubertal growth spurt were also found to be more likely to require insulin treatment if they went on to develop type 2 diabetes.

While the researchers are not very clear about the underlying mechanisms of this association, they believe that that early puberty may lead to build-up of excess fat in the abdominal area. This may in turn leads to high blood pressure, diabetes, and abnormal lipid levels, which are all risk factors for cardiac and metabolic disease.

Earlier studies have already found an association between a high adult BMI and a higher risk for type 2 diabetes. It is also known that boys with a high BMI in childhood or during puberty have a greater diabetes risk. Some studies have also linked earlier onset of puberty in girls, as defined by the beginning of menstruation, to a higher risk of diabetes.

Jenny Kindblom, co-author of the new study, noted that their findings suggest that early puberty could be a novel independent risk factor for type 2 diabetes in men. She believes that a continuous monitoring of height and weight development during both childhood and adolescence may help identify individuals with increased risk of type of diabetes.

Type 2 diabetes occurs when your body either resists the effects of insulin or doesnt produce enough insulin to maintain normal glucose levels. Insulin is a hormone secreted by the pancreas and it helps regulate the movement of sugar into your cells.

Signs and symptoms of type 2 diabetes often develop gradually over time. They can be so mild that you can have type 2 diabetes for years and not know about it. Here are some symptoms to watch out for:

Unfortunately, theres no cure for type 2 diabetes. However, you can control the disease by maintaining a healthy weight, eating well and exercising. Some people may need diabetes medications or insulin therapy to manage their blood sugar levels.

Published : May 31, 2020 7:15 pm | Updated:June 1, 2020 8:13 am

Read the rest here:
Men who had early puberty at higher risk of developing type 2 diabetes - TheHealthSite

KATONAH, N.Y. (PRWEB) June 01, 2020

In her upcoming book Actually, I Can: Growing Up with Type 1 Diabetes, A Story of Unexpected Empowerment (T1D Media) Morgan Panzirer writes: It has made me appreciate every hour, every minute, and every second I stand on this Earth. But the truth is everyone should live this way, because you dont know if youll receive life-changing news tomorrow, and you dont know if today is your last day. Everyone has obstacles in their lives; its just the way life is. But you dont have to sit there and let them beat you down. Defeat them. Strength is a choice, and if you tell yourself you can get through whatever youre battling, then you can.

From the diagnosis at six years old with the autoimmune disease, through all of the challenges battling it, and everything she and her parents have learned Morgans goal is to help other families and children facing Type 1, and to show everyone it can be viewed as an opportunity rather than an obstacle.

Robin Roberts, co-Anchor Good Morning America, says: An inspiring young woman whose insight into her Type 1 diabetes will help others, and their families, to confront the vulnerabilities of the disease. Readers will learn from Morgan how to manage these issues with composure and strength.

Emmy-award winning medical correspondent and senior health editor for NBC, Dr. Max Gomez, explains: What I took away from Actually, I Can was not the charmed life, meeting celebrities and traveling the world. It was that after confronting the awfulness of her diagnosis, Morgan was able to face her disease and take control of it, including the difficult, painful ups and downs.

Founder of diaTribe.org Kelly L. Close reviews: This is a story about family, faith, and friendships, and includes remarkable encounters with politicians, pop stars, and even the Pope. Every teenager with diabetes should read this book. So, too, should their parents and their health care providers as well. A triumph.

Morgan has an authentic voice in the diabetes patient perspective. She unabashedly stares down and addresses the unrelenting challenges one faces in diabetes diagnosis and management, sans sugarcoating. Accompanied by gritty optimism, her impressive insight on progressing diabetes research, emerging tech and medications will impress readers with a resilient hope that a fulfilled and healthy life is possible, responds Gary Hall, Jr., first Olympian/Gold Medalist with Type One Diabetes.

About the AuthorA member of the Villanova University Equestrian Team, and a biology major planning to attend medical school for pediatric endocrinology, Morgan Panzirer has traveled the world discussing her disease, including a trip to Rome to meet with the Pope. Morgan is available as a keynote speaker and media presenter with invaluable information on Type 1 Diabetes, self-care and perseverance speaking to groups and offering copies of Actually, I Can. for the audience.

Share article on social media or email:

Read more here:
A New Book for Anyone With Type 1 Diabetes "Actually, I Can." by 19-year-old Author Gives Insight and Inspiration - PR Web

Insulet(NASDAQ:PODD)earlier this month reported first-quarter 2020 results. The tubeless insulin pump specialist's results were quite strong, especially in light of the COVID-19 pandemic.

In 2020, shares of thehealthcare companyare up 10.2% through the end of May, outpacing the broader market, which is down about 5% because of the pandemic. Insulet stock remains a huge winner over the intermediate and long terms. Over the past five years, it's gained 567%, versus the broader market's 60% return.

Here's how the quarter worked out for Insulet and its investors.

Image source: Insulet.

Metric

Q1 2020

Q1 2019

Change

Revenue

Operating income

Net income

Earnings per share (EPS)

Data source: Insulet.

Revenue easily beat Insulet's guidance of growth of 17% to 20% year over year. For context, in the prior quarter, revenue grew 27% year over year.

The year-over-year decline on the bottom line was driven by an increase in interest expense.

Here's what CEO Shacey Petrovic had to say in the press release:

Insulet entered 2020 with positive momentum, making progress toward our strategic objectives and achieving strong revenue growth ahead of expectations. The efficiency and redundancy we have built in our supply chain and manufacturing operations enabled us to meet customer demand without interruption during this challenging time. We believe that our proven, durable annuity business model will continue to generate double-digit revenue growth in 2020. We remain confident we have the right strategic framework to effectively advance our mission, drive sustainable long-term growth throughout our global business, and to continue to create shareholder value.

On the earnings call, CFO McMillan quantified what Petrovic termed the company's "annuity business model," or what others might consider a razor-and-blade model: "Historically, new Omnipod starts within any given quarter contributed approximately 10% of revenue." In other words, the vast majority of quarterly revenue has come from existing Omnipod users purchasing new pods.

The Omnipod has no upfront cost, as it's a pay-as-you-go product, which means sales should hold up better in a recessionary environment relative to products that have considerable upfront costs.

Insulet's Q1 results were quite robust despite headwinds presented by the pandemic.

Unlike many companies, it didn't lower or pull its full-year 2020 guidance. Management reaffirmed its previously issued 2020 outlook of revenue growth of 14% to 18% over 2019. However, it did say that it now expects revenue to come in at the low end of this outlook. The company doesn't issue earnings guidance.

Due to the pandemic, Insulet's U.S. launch of its Omnipod Horizon automated insulin delivery system, which uses aDexCom(NASDAQ:DXCM) continuous glucose monitor (CGM) to dose insulin, has been pushed back. Management now expects this launch to occur in the first half of 2021, rather than in late 2020, Petrovic said on the earnings call.

Go here to read the rest:
This Diabetes Company's Q1 Earnings Reflect the Resiliency of Its Business Model - The Motley Fool

The global Diabetes Care Drugs market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Diabetes Care Drugs market player in a comprehensive way. Further, the Diabetes Care Drugs market report emphasizes the adoption pattern of the Diabetes Care Drugs across various industries.

The Diabetes Care Drugs market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Diabetes Care Drugs market provides a birds eye view of the current proceeding within the Diabetes Care Drugs market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Diabetes Care Drugs market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2554778&source=atm

The key players covered in this studyNovo NordiskSanofiEli LillyBioconAstraZenecaBristol Myers SquibbBoehringer IngelheimMylanPfizerJohnson & JohnsonMerckNovartisAstellasTeva

Market segment by Type, the product can be split intoOral Anti-diabetic DrugsInsulinsNon-insulin Injectable DrugsOther

Market segment by Application, split intoHospitalMedical Research InstituteClinicOther

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Diabetes Care Drugs status, future forecast, growth opportunity, key market and key players.To present the Diabetes Care Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Diabetes Care Drugs are as follows:History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2554778&source=atm

The Diabetes Care Drugs market report offers a plethora of insights which include:

The Diabetes Care Drugs market report answers important questions which include:

The Diabetes Care Drugs market report considers the following years to predict the market growth:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2554778&licType=S&source=atm

Why Choose Diabetes Care Drugs Market Report?

Diabetes Care Drugs Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

See the rest here:
COVID-19: Responding to the business impacts of Diabetes Care Drugs Market-Segment Market Trends, Analysis and Forecast 2019 2024 - Cole of Duty

President Donald Trump pondered if he should take insulin while announcing a plan to reduce the price of the drug typically prescribed to diabetics. USA TODAY

WASHINGTON President Donald Trump pondered on Tuesday whether he should be taking insulin,a hormone typically prescribed to diabetics, during an announcement foraplan which would aim to drastically reduce the price of insulin for people on Medicare.

"I don't use insulin," Trump said. "Should I be? Huh? I never thought about it. But I know a lot of people are very badly affected, right? Unbelievable."

In people with Type 1 diabetes, the pancreas cant make insulin. Those with the condition require several doses of insulin a day.

'Contain potentially misleading information': Twitter fact-checks Trump's tweets

All people with Type 1 and some with Type 2, whose body doesnt use insulin the way it should, need the drug.

Trump has no known history of diabetes.

More than 30.3 million people in the U.S. have diabetes, and 90% to 95% of them have Type 2 diabetes, according to the 2017 National Diabetes Statistics Report. Unlike people with Type 1 diabetes, those with Type 2 can in many caseslessen their dependence on insulin through healthier diet and exercise.

Clyburn: I 'cringed' at Biden 'you ain't black' comment but compare him 'to the alternative, not the Almighty'

Asked later by a reporter why he would take insulin, Trump asked surgeon general Jerome Adams to answer, in which he explained to the president that, "Your body, Mr. President, actually makes insulin endogenously."

He continued that "people such as you and I, we make our own insulin. So yes we do utilize insulin, but we make it ourselves.

Trump saysmost senior Medicare recipients willget prescription plans that would cap copay costs, giving them access to several types of insulinat no more thana $35 copayfor a month's supply, underneath the planannounced Tuesday.

Struggling to stay alive: Rising insulin prices cause diabetics to go to extremes

The price of modern versions of a drug that more than 7 million Americans need to livenearly tripled from 2002 to 2013, according to onestudy.Type 1 diabetics paid an average of $5,705 for insulin in 2016 nearly double what they paid in 2012, according to the Health Care Cost Institute.

Costs for insulin have continuedto rise, so much so that almost half of people with diabeteshave temporarily skipped taking their insulin, according to a 2018 survey by UpWell Health, a Salt Lake City company that provides home delivery of medications and supplies for chronic conditions.

Contributing:Ken Alltucker, USA TODAY;Megan Henry, The Columbus Dispatch.

Read or Share this story: https://www.usatoday.com/story/news/politics/2020/05/26/trump-asks-whether-he-should-taking-insulin-despite-not-being-diabetic/5263965002/

Visit link:
Trump asks whether he should take insulin despite not being diabetic - USA TODAY